Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. - Wikidata - wikimedia - TriplyDB

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.

http://www.wikidata.org/entity/Q33618126

about

Targeted immunotherapy for pediatric solid tumors Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy Targeting the apoptosis pathway in hematologic malignancies Getting TRAIL back on track for cancer therapy Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma A set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in lung cancer.Antibody phage display libraries: contributions to oncology.Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma.Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase.Combination effects of SMAC mimetic birinapant with TNFα, TRAIL, and docetaxel in preclinical models of HNSCC.Enhancing the bystander killing effect of an oncolytic HSV by arming it with a secretable apoptosis activator.Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody.Regulating TRAIL receptor-induced cell death at the membrane : a deadly discussion On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics.Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma.Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors.Applications of minimal physiologically-based pharmacokinetic models.TRAIL (TNF-related apoptosis-inducing ligand) regulates adipocyte metabolism by caspase-mediated cleavage of PPARgamma.Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.Advances in targeting cell surface signalling molecules for immune modulation Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy Therapeutic applications of TRAIL receptor agonists in cancer and beyond.Physapubescin selectively induces apoptosis in VHL-null renal cell carcinoma cells through down-regulation of HIF-2α and inhibits tumor growth TRAIL on trial: preclinical advances in cancer therapy TRAIL-death receptor endocytosis and apoptosis are selectively regulated by dynamin-1 activation.Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways.TRAIL receptor signaling and therapeutics.Towards novel paradigms for cancer therapy.Harnessing the cell death pathway for targeted cancer treatment.The therapeutic potential of TRAIL receptor signalling in cancer cells.TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment.Apoptosis-modulating drugs for improved cancer therapy.Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?Death receptors as targets in cancer

P2860

Q26747703-0DFC7339-5D2F-4218-A389-565B13E5712C Q26771601-019B36E0-D0B6-4C3E-AF1C-C00646416A9F Q26852287-49C6DC40-BA4B-494E-9DA1-ABE0C6935110 Q26993238-A7209B5D-DDA6-4D84-B612-34FF4614A720 Q27024422-542DDCF7-E04D-4B2B-AD04-FE139C2FF8D3 Q27027460-85F0A18A-4FB9-4537-9E66-2A883EEBD679 Q28474017-A84C189D-2C7A-44A8-9DE0-E6BCB8A7C71F Q30361915-F628A42D-72F6-4ED1-8906-80B37F9AEC8A Q34323991-EFF1188D-F1D1-42A9-9288-9187B7997016 Q34429203-C0D3FF2D-3DF9-4276-B9DC-EFAC66F547B2 Q34464915-C22D90EE-1919-4B12-A1FE-71B11D664D83 Q35005616-14BA9412-36E9-41D1-B691-6DE28920DB5E Q35038107-8CF5A547-8FA1-47BB-8E4B-BBF7E49EF0BD Q35106930-EC0D1705-F1C5-4BAB-BE7A-FD4EAE796452 Q35154965-D89A8BD9-E0F7-4D90-9115-9B4E05D9131F Q35223910-96A07346-4875-41B0-8DA3-03E69E93DFA1 Q35480734-265CCD15-F61A-49A7-8FFB-E59F9FAC79E4 Q35853714-3A98435E-67B7-47A4-84BF-6826D376F101 Q35936863-7839CFBC-AC5B-47BF-B0F4-D99A0C08AB29 Q36079365-70C6CDBE-6EBC-40C6-9EFA-AE67BA892237 Q36389203-6B780F96-C67E-4FAB-B4F6-467A5C5DD605 Q36517093-810B0BC5-1785-4AD5-8F7E-256BA2755EAC Q36586540-21E49159-BDB5-4BC9-8946-72DA837B3EEE Q36938811-DB81DC3A-1614-4288-A938-FF09300CD9A9 Q36973787-D09A3852-17FF-45B3-9BA4-D2A4CB38E618 Q37071019-EDABBB8B-4E1D-4E59-9F14-0070EE57B26F Q37114025-1BEB6051-FE0D-4272-AE75-3EA8B807E214 Q37223809-529DF78D-1319-4588-A6B0-E164F85AEE0A Q37433463-55422BAC-0F34-4AF6-BB6C-2647A3AD4E15 Q37599015-3EE64A8A-ABB1-41E0-8A7B-7EB84777C383 Q37680195-8A9E0795-0FE8-4822-A5D5-D09170449906 Q37785559-B2B41A66-1065-4EAE-8694-B8EE4CA3ECE7 Q37799251-2BB3A4CC-B501-405E-A8EA-05657CC39AF9 Q37942090-B92D909E-9A04-4C1C-B86D-850D7131B4E1 Q37962655-79AA8978-7D38-478D-B0E9-32C70A7DC8CA Q37972139-22D6BB8B-A171-43DE-86B7-B807DC3DAB41 Q38005914-C3537A8B-9512-4CF5-BEEA-5459D24927C0 Q38068494-4052E587-0735-4916-96CD-4A146308E1B6 Q38074430-E9AFF9B9-30AA-4363-B7DB-9A4728A4060D Q38103591-99F67D59-4107-4F6F-AF06-6445BA9BC41A

P2860

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.

http://www.wikidata.org/entity/Q33618126

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Phase I and pharmacokinetic st ...... ts with advanced solid tumors.

@ast

Phase I and pharmacokinetic st ...... ts with advanced solid tumors.

@en

type

label

Phase I and pharmacokinetic st ...... ts with advanced solid tumors.

@ast

Phase I and pharmacokinetic st ...... ts with advanced solid tumors.

@en

prefLabel

Phase I and pharmacokinetic st ...... ts with advanced solid tumors.

@ast

Phase I and pharmacokinetic st ...... ts with advanced solid tumors.

@en

P1433

Q33618126-BD7DD184-C39C-4BCC-9B37-584808231DA0

P1476

Q33618126-E4036443-D8B1-4AFA-B1DD-B19E717AA471

P2093

Q33618126-0358B8A2-CD75-456B-96CF-DDD88669CE8E

Q33618126-251C6B82-7310-4014-88A7-0541C12CEDDD

Q33618126-693FC59F-D586-45F9-8405-0C23812BF849

Q33618126-6963017F-FA97-43EC-BA78-2E3510509C62

Q33618126-81030E0F-8820-484A-BDE0-600515E59B88

Q33618126-8EDB02A5-C660-4D44-A8AD-AF3EAB445446

Q33618126-9BA30911-FD50-4BAD-B789-F27F2A93B1DD

Q33618126-D4937813-2B01-412E-A1A5-E3C18C03CC87

Q33618126-EF8F4A75-9993-4328-96FC-6A8907132D36

P2860

Q33618126-108ACFEC-DCC0-46FD-863E-962430364C69

Q33618126-13C86FF6-B97F-4EB9-9D1B-AD8754F9A993

Q33618126-16C56BB9-E347-4FB0-8568-684B77064941

Q33618126-18F165B5-736F-4400-95FF-C102AD85A7FA

Q33618126-1D88E5B6-F4AC-4843-A8F7-52485AB823B6

Q33618126-30D9B0AF-F181-4EED-AF88-2772BE4B75EA

Q33618126-41934637-52DF-43A7-82B3-CE900D33DC61

Q33618126-55F130C5-5EDE-408E-BCA2-04A4C0F5CAA2

Q33618126-5A1C08FB-BC20-4A7E-9307-E0DD98369003

Q33618126-62E3D0F2-6A23-4BF6-9143-F7C40C92FFCA

P304

Q33618126-649485E6-34A2-4F4B-8EAB-EB157CC41E34

P31

Q33618126-B33B19F5-558A-4A9D-A8F3-B40DDECC6A88

P356

Q33618126-FCB1B3A2-C810-4AF6-9947-414D9A2DBBC6

P433

Q33618126-D262440E-F7CF-4DE9-BFC7-4341FBD6A771

P478

Q33618126-0EBF9965-BF20-4EDE-9EBF-B0E2B0808AC5

P577

Q33618126-7CDFDFD4-9302-4C18-AF53-0AE1FD67D012

P5875

Q33618126-2EA9B30E-FC9F-4CF4-99F2-25DA171DA8BC

P698

Q33618126-83EC7954-C30F-4F7E-A24C-D1E5C7C169DC

P932

Q33618126-14CE27F4-CAA4-4428-B753-B2B6B168AE5D

P356

P1433

Annals of Oncology

P1476

Phase I and pharmacokinetic st ...... ts with advanced solid tumors.

@en

P2093

A Patnaik

http://www.w3.org/2001/XMLSchema#string

A W Tolcher

http://www.w3.org/2001/XMLSchema#string

B I Sikic

http://www.w3.org/2001/XMLSchema#string

G A Fisher

http://www.w3.org/2001/XMLSchema#string

H A Wakelee

http://www.w3.org/2001/XMLSchema#string

M Mita

http://www.w3.org/2001/XMLSchema#string

N L Fox

http://www.w3.org/2001/XMLSchema#string

R Miceli

http://www.w3.org/2001/XMLSchema#string

S J Ullrich

http://www.w3.org/2001/XMLSchema#string

P2860

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors

Apo2L/TRAIL and its death and decoy receptors.

Death to the bad guys: targeting cancer via Apo2L/TRAIL.

Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.

Drug evaluation: lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor 2.

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.

Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression.

Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells.

P304

376-381

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDP292

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26696158

http://www.w3.org/2001/XMLSchema#string

P698

19633048

http://www.w3.org/2001/XMLSchema#string

P932

2813303

http://www.w3.org/2001/XMLSchema#string